Vonvendi FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 2, 2022.
FDA Approved: Yes (First approved December 8, 2015)
Brand name: Vonvendi
Generic name: von willebrand factor (recombinant)
Dosage form: for Injection
Company: Baxalta Incorporated
Treatment for: von Willebrand Disease
Vonvendi (von Willebrand factor (recombinant)) is a recombinant von Willebrand factor for the treatment of von Willebrand disease(VWD).
- Vonvendi is indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease(VWD) for:
- On-demand treatment and control of bleeding episodes.
- Perioperative management of bleeding.
- Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand therapy.
- Vonvendi is administered via intravenous infusion.
Development timeline for Vonvendi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
